Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

AB Science

- PMLiVE

AL-S Pharma release new data from AP-101 phase 2 trial for ALS

ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord

Biogen Idec building

Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

- PMLiVE

Eli Lilly and Alchemab Therapeutics enter ALS agreement worth up to $415m

The deal follows the companies’ earlier partnership to advance candidates for the neurodegenerative disease

- PMLiVE

Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

The neurodegenerative disease affects approximately 30,000 people in the US

- PMLiVE

Researchers develop new approach to target cells affected by motor neurone disease

The technique could lead to safer and more effective gene therapies for the neurodegenerative disease

- PMLiVE

LifeArc and King’s College London partner to accelerate treatment for motor neurone disease

The rare neurodegenerative disease affects one in every 300 people in the UK

- PMLiVE

NIHR partners with Motor Neurone Disease Association for MND research

The partnership will speed up the discovery of treatments and insights for MND

- PMLiVE

Innovate UK awards Sano Genetics £330,000 grant for ALS study

The project will chart the psychological impacts of having a genetic predisposition to ALS

Biogen Idec building

Biogen’s Qalsody granted FDA accelerated approval for rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all cases

- PMLiVE

Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

The neurodegenerative disease affects approximately 27,000 people in the US

- PMLiVE

UK Government commit £50m to motor neurone disease research

The pledged funding is being placed into the hands of researchers ‘as quickly as possible’

- PMLiVE

Verge Genomics begins human trials with AI-sourced ALS drug

VRG50635 was discovered by the company’s all-in-human, AI-powered platform

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links